Saturday 17 October 2026
Export SPRC’s income statement to Excel — free account
SciSparc Ltd.
SPRC Healthcare Biotechnology
SciSparc Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $856,000.00, down 34.5% from fiscal 2024. Operating cash flow growth for three consecutive years.
1.70
0.30
−15.00%
Follow SPRC
| Jun '26 | Jun '25 | Jun '24 | Jun '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | — | 0.00 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (236.32) | |
P/B ratio |
— | — | — | 112.72 | |
Price to Tangible BV |
— | — | — | 331.60 | |
EV/Sales |
— | — | — | 0.00 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (57.46) | |
EV/FCF |
— | — | — | (57.58) | |
Quick Ratio |
0.79 | 0.39 | 1.63 | 0.96 | |
Current Ratio |
0.87 | 0.55 | 1.86 | 1.17 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
14.49% | 47.23% | 0.00% | 0.00% | |
Debt/Equity |
0.24 | (29.96) | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
— | 0.00 | 0.00 | 1.12 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 0.00% | |
Intangible Assets out of Total Assets |
0.67 | 0.27 | 0.29 | 0.45 | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
— | — | — | 0.00 | |
Graham Number |
— | — | — | 0.00 | |
Earnings Yield |
— | — | — | (2.64%) | |
Free Cash Flow Yield |
— | — | — | (1.73%) | |
Revenue per Share |
— | — | — | 0.00 | |
Operating CF per Share |
— | 0.00 | 0.00 | (11.42) | |
Capex per Share |
— | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
— | 0.00 | 0.00 | (11.42) | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | — | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
— | (1.86) | (2.20) | (3.23) | |
Working Capital |
(0.81) | (2.29) | 1.56 | 0.53 | |
Capital Expenditures |
— | — | 0.00 | — | |
Net Current Asset Value |
(1.66) | (2.47) | 1.53 | 0.53 | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Receivables |
0.37 | 0.54 | 1.44 | 0.79 | |
Average Payables |
1.02 | 0.84 | 1.18 | 0.80 | |
Average Inventory |
0.37 | — | — | — | |
Average Assets |
14.55 | 9.78 | 10.20 | 9.12 | |
Average Common Equity |
8.86 | 1.48 | 8.40 | 7.18 |
Columns are period end dates · fundamentals updated 2 Oct 2026